Condition: Head and Neck Squamous Cell Carcinoma (HNSCC) · HPV (Human Papillomavirus)-Associated Carcinoma · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Sponsor: Cellid Co., Ltd.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18. This clinical trial for BVAC-E6E7 consists of two phases: PhaseⅠfocuses on safety and tolerance to determine the maximum tolerated dose (MTD), while Phase Ⅱ evaluates its efficacy.
This description comes directly from the study's public registry record.
Wu Hyun Kim, D.V.M · 02-3285-7863 · whkim@cellid.co.kr
Always discuss trial participation with your own doctor first.
| Seoul National Univesity Hospital | Seoul, South Korea | Recruiting |
| Sevrance Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06797986